Kenneth Francis Hofland

Summary

Publications

  1. ncbi request reprint Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin
    Kenneth Francis Hofland
    Laboratory of Experimental Medical Oncology, Finsen Center, Copenhagen, Denmark
    Clin Cancer Res 11:3915-24. 2005
  2. ncbi request reprint Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors
    Kenneth Francis Hofland
    Laboratory of Experimental Medical Oncology, The Finsen Center, Copenhagen, Denmark
    Clin Cancer Res 11:6722-9. 2005
  3. ncbi request reprint Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent
    Patricia E Schroeder
    Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, Canada R3T 2N2
    Cancer Chemother Pharmacol 53:91-3. 2004
  4. ncbi request reprint Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide
    Patricia E Schroeder
    Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada
    Cancer Chemother Pharmacol 52:167-74. 2003
  5. ncbi request reprint A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo
    Morten Grauslund
    Experimental Pathology Unit, Department of Pathology, Rigshospitalet afs 3731, Biocenter, Bygning 2, 3 sal, Ole Maaløes Vej 5, DK 2100 Copenhagen O, Denmark
    Mol Pharmacol 72:1003-14. 2007

Collaborators

  • Lars H Jensen
  • B B Hasinoff
  • S W Langer
  • Patricia E Schroeder
  • Maxwell Sehested
  • Morten Grauslund
  • Peter Buhl Jensen
  • Annette Füchtbauer
  • Annemette Vinding Thougaard
  • Peter B Jensen
  • Peter Hansen Hjorth
  • Ernst Martin Füchtbauer

Detail Information

Publications5

  1. ncbi request reprint Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin
    Kenneth Francis Hofland
    Laboratory of Experimental Medical Oncology, Finsen Center, Copenhagen, Denmark
    Clin Cancer Res 11:3915-24. 2005
    ..Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity...
  2. ncbi request reprint Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors
    Kenneth Francis Hofland
    Laboratory of Experimental Medical Oncology, The Finsen Center, Copenhagen, Denmark
    Clin Cancer Res 11:6722-9. 2005
    ..We hypothesized that dexrazoxane combined with escalated etoposide doses might improve the efficacy of cerebral radiotherapy...
  3. ncbi request reprint Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent
    Patricia E Schroeder
    Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, Canada R3T 2N2
    Cancer Chemother Pharmacol 53:91-3. 2004
    ....
  4. ncbi request reprint Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide
    Patricia E Schroeder
    Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, R3T 2N2, Winnipeg, Manitoba, Canada
    Cancer Chemother Pharmacol 52:167-74. 2003
    ..In this phase I/II trial dexrazoxane was used as a rescue agent to reduce the extracerebral toxicity of etoposide...
  5. ncbi request reprint A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo
    Morten Grauslund
    Experimental Pathology Unit, Department of Pathology, Rigshospitalet afs 3731, Biocenter, Bygning 2, 3 sal, Ole Maaløes Vej 5, DK 2100 Copenhagen O, Denmark
    Mol Pharmacol 72:1003-14. 2007
    ..The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed...